Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived Therapies.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
Innovation is a hallmark of organ, tissue, and cell transplantation. The development of new treatments derived from these substances of human origin (SoHO) has rapidly evolved in recent years. Despite the great benefits that these innovative therapies could bring to patients, significant difficulties have arisen in making them equitably and widely accessible. Herein, we identify and address 4 challenges to promote innovation in this field in a collaborative, sustainable, and transparent manner and propose some concrete solutions applicable to SoHO-derived treatments, ranging from cell therapies to solid organ transplantation. Regulators, health policymakers, and government officials are recommended to incorporate specific elements into the regulatory frameworks of their respective jurisdictions, although regulatory convergence and equivalent quality and safety standards applicable to SoHO at a global level would be needed. An innovation-driven regulatory environment, respectful with the human origin and in accordance with the altruistic donation of SoHO, should be encouraged to improve the safety, effectiveness, accessibility, and affordability of SoHO and to promote collaboration between countries and between public and private sectors. This overview is the outcome of a working group focused on "Innovation in the donation and clinical application of SoHO" as part of the international Summit "Towards Global Convergence in Transplantation: Sufficiency, Transparency and Oversight" convened by the Organización Nacional de Trasplantes under the Spanish Presidency of the Council of the European Union in November 2023 and cosponsored by the Council of Europe, the World Health Organization, the Transplantation Society, and the European Society for Organ Transplantation.
Identifiants
pubmed: 39437372
doi: 10.1097/TP.0000000000005169
pii: 00007890-990000000-00905
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
WHO-ONT Global Observatory on Donation and Transplantation. International report on organ donation and transplantation activities. 2022. Available at https://www.transplant-observatory.org/wp-content/uploads/2022/12/2021-data-global-report-1.pdf. Accessed June 13, 2024.
Giwa S, Lewis JK, Alvarez L, et al. The promise of organ and tissue preservation to transform medicine. Nat Biotechnol. 2017;35:530–542.
Institute for Health Metrics and Evaluation. Global burden of disease. Available at https://www.healthdata.org/research-analysis/gbd. Accessed June 13, 2024.
Cuende N, Rasko JEJ, Koh MBC, et al. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy. 2018;20:1401–1413.
De Luca M, Cossu G. Cost and availability of novel cell and gene therapies: can we avoid a catastrophic second valley of death? EMBO Rep. 2023;24:e56661.
Council of Europe. European Committee on Organ Transplantation. Position statement on risk of commodification of substances of human origin. PA/PH/TO (22) 11 DEF. Available at https://www.edqm.eu/en/areas-of-work-transplantation#{%221180609%22:[0]}. Accessed June 13, 2024.
World Health Organization. World Health Assembly. Resolution 63.22 on human organ and tissue transplantation. Available at https://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R22-en.pdf. Accessed June 13, 2024.
World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Available at https://apps.who.int/iris/bitstream/handle/10665/341814/WHO-HTP-EHT-CPR-2010.01-eng.pdf?sequence=1&isAllowed=y. Accessed June 13, 2024.
World Medical Association. WMA statement on organ and tissue donation. Available at https://www.wma.net/policies-post/wma-statement-on-organ-and-tissue-donation/. Accessed June 13, 2024.
Sánchez-Ibañez J, Humphreys C, Lomero M, et al. Tissue and cell donation: recommendations from an international consensus forum. Transplant Direct. 2023;9:e1466.
Council of Europe Committee on Bioethics. Guide for the implementation of the principle of prohibition of financial gain with respect to the human body and its parts from living or deceased donors. Available at https://rm.coe.int/guide-financial-gain/16807bfc9a. Accessed June 13, 2024.
Council of Europe. Convention for the protection of Human Rights and Dignity of the human being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. Available at https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/164. Accessed June 13, 2024.
Council of Europe. Additional protocol to the convention on human rights and biomedicine concerning transplantation of organs and tissues of human origin. Available at https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/186. Accessed June 13, 2024.
Pirnay JP, Baudoux E, Cornu O, et al. Access to human tissues for research and product development: from EU regulation to alarming legal developments in Belgium. EMBO Rep. 2015;16:557–562.
Cuende N, Vilarrodona A, Vuelta E, et al. Addressing risks derived from the commodification of substances of human origin: a European proposal applicable worldwide. Transplantation. 2023;107:867–877.
World Health Organization. WHO principles on the donation and management of blood, blood components and other medical products of human origin. Available at https://apps.who.int/iris/bitstream/handle/10665/274793/A70_19-en.pdf?sequence=1&isAllowed=y. Accessed June 13, 2024.
Council of Europe. European Treaty Series—No. 164. Convention for the protection of human rights and dignity of the human being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. Oviedo, 4.IV.1997. Available at https://rm.coe.int/168007cf98. Accessed June 13, 2024.
Rosenberg N, Stolwijk NN, van den Berg S, et al. Development of medicines for rare diseases and inborn errors of metabolism: toward novel public-private partnerships. J Inherit Metab Dis. 2023;46:806–816.
Izeta A, Herrera C, Mata R, et al. Cell-based product classification procedure: what can be done differently to improve decisions on borderline products? Cytotherapy. 2016;18:809–815.
World Health Organization. WHO considerations on regulatory convergence of cell and gene therapy products. Available at https://cdn.who.int/media/docs/default-source/biologicals/ecbs/who-public-consultation_cgtp-white-paper_16_dec_2021.pdf?sfvrsn=18f6c549_5. Accessed June 13, 2024.
World Health Organization Expert Committee on Biological Standardization. Considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products. Available at https://cdn.who.int/media/docs/default-source/biologicals/annex-3---hcts-atmps-regulatory-considerations---clean-for-posting---12-may-2023.pdf?sfvrsn=cc1f9a8a_1&download=true. Accessed June 13, 2024.
Wang A, Ribeiro RVP, Ali A, et al. Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs. Sci Transl Med. 2022;14:eabm7190.
Cuende N, Rico L, Herrera C. Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation? Stem Cells Transl. Med. 2012;1:403–408.
Trias E, Juan M, Urbano-Ispizua A, et al. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplant. 2022;57:156–159.
Thielen FW, Heine RJSD, Berg SVD, et al. Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma. Cytotherapy. 2022;24:1245–1258.
Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: a call to action. Sci Transl Med. 2017;9:eaag0426.
Cuende N, Herrera C, Keating A. When the best is the enemy of the good: the case of bone-marrow mononuclear cells to treat ischemic syndromes. Haematologica. 2013;98:323–324.
European Directorate for the Quality of Medicines & HealthCare. Guide to the quality and safety of organs for transplantation. 8th ed. Available at https://freepub.edqm.eu/publications/PUBSD-88/detail. Accessed June 13, 2024.
European Directorate for the Quality of Medicines & HealthCare. Guide to the quality and safety of tissues and cells for human application. 5th ed. Available at https://freepub.edqm.eu/publications/AUTOPUB_17/detail. Accessed June 13, 2024.
European Union. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Available at https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32004L0023. Accessed June 13, 2024.
European Union. Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells. Available at https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:294:0032:0050:EN:PDF. Accessed June 13, 2024.
European Union. Directive 2010/45/EU of the European Parliament and of the Council of 7 July 2010 on standards of quality and safety of human organs intended for Transplantation. Available at https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010L0053. Accessed June 13, 2024.
EUROGTP II Guide. Good practices for evaluating quality, safety and efficacy of novel tissue and cellular therapies and products. Guidance, methodologies and tools. Available at http://www.goodtissuepractices.site/docs/EuroGTP_II_Guide.pdf. Accessed June 13, 2024.
GAPP. Good practice guideline to authorization on preparation processes in blood, tissue and cells establishments. Available at https://www.gapp-ja.eu/wp-content/uploads/2022/01/GAPP-volume-Guide-and-Technical-Annexes.pdf. Accessed June 13, 2024.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH guideline for good clinical practice E6(R2). Available at https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed June 13, 2024.
McCulloch P, Altman DG, Campbell WB, et al.; Balliol Collaboration. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374:1105–1112.
Ronco V, Dilecce M, Lanati E, et al. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? J Pharm Policy Pract. 2021;14:30.
Liu A. A $3M gene therapy: bluebird bio breaks its own pricing record with FDA approval of Skysona [Fierce pharma]. Available at https://www.fiercepharma.com/pharma/3m-gene-therapy-bluebird-breaks-own-record-fda-approval-skysona#:~:text=The%20company%20is%20charging%20%243,priciest%20therapy%20in%20the%20world. Accessed June 13, 2024.
Young CM, Quinn C, Trusheim MR. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discov Today. 2022;27:17–30.
Quinn C, Young C, Thomas J, et al.; MIT NEWDIGS FoCUS Writing Group. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health. 2019;22:621–626.
Kamusheva M, Turcu-Stiolica A, Gierczyński J, et al. Do advanced therapies have a future in the low- and middle-income countries—the case of Bulgaria, Romania, and Poland. Front Public Health. 2021;9:729847.
Ministerio de Sanidad. Propuesta de precio de medicamentos de terapia avanzada de fabricación no industrial. Ficha normalizada para el cálculo del precio. Available at https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/docs/20191014_Anexo1_Propuesta_precio_MTA_no_industrial_SNS_CISNS.pdf. Accessed June 13, 2024.
Ran T, Eichmüller SB, Schmidt P, et al. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int J Cancer. 2020;147:3438–3445.
Juan M, Delgado J, Calvo G, et al. Is hospital exemption an alternative or a bridge to European medicines agency for developing academic chimeric antigen receptor T-cell in Europe? Our experience with ARI-0001. Hum Gene Ther. 2021;32:1004–1007.
Toumi M, Dabbous O, Aballéa S, et al. Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. Expert Rev Pharmacoecon Outcomes Res. 2023;23:483–497.
Drummond M, Ciani O, Fornaro G, et al. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Serv Res. 2023;23:484.
World Health Organization. WHO guideline on country pharmaceutical pricing policies. 2nd ed. Available at https://www.who.int/publications/i/item/9789240011878. Accessed June 13, 2024.
Gonçalves E. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. Eur J Health Econ. 2022;23:155–163.
PipelineReview. MolMed informs on its decision to withdraw the Conditional Marketing Authorization of Zalmoxis. Available at https://pipelinereview.com/index.php/2019101172535/DNA-RNA-and-Cells/MolMed-informs-on-its-decision-to-withdraw-the-Conditional-Marketing-Authorization-of-Zalmoxis.html. Accessed June 13, 2024.
American Society of Hematology. Bluebird bio ends commercial operations in Europe. Available at https://ashpublications.org/ashclinicalnews/news/5779/Bluebird-Bio-Ends-Commercial-Operations-in-Europe. Accessed June 13, 2024.
Izeta A, Cuende N. Regulation of advanced therapies in Europe: are we on the right track? Cell Stem Cell. 2023;30:1013–1016.